TY  - JOUR
AU  - Rahbar, Kambiz
AU  - Essler, Markus
AU  - Pabst, Kim M
AU  - Eiber, Matthias
AU  - Fougère, Christian la
AU  - Prasad, Vikas
AU  - Rassek, Philipp
AU  - Hasa, Ergela
AU  - Dittmann, Helmut
AU  - Bundschuh, Ralph A
AU  - Fendler, Wolfgang P
AU  - Kurtinecz, Milena
AU  - Schmall, Anja
AU  - Verholen, Frank
AU  - Sartor, Oliver
TI  - Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 4
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-00703
SP  - 574 - 578
PY  - 2023
AB  - The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59
KW  - Male
KW  - Humans
KW  - Lutetium: adverse effects
KW  - Radium: adverse effects
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Treatment Outcome
KW  - Retrospective Studies
KW  - Prostate: pathology
KW  - Prostate-Specific Antigen
KW  - Dipeptides: adverse effects
KW  - Heterocyclic Compounds, 1-Ring: adverse effects
KW  - 177Lu-PSMA (Other)
KW  - 223Ra (Other)
KW  - metastatic castration-resistant prostate cancer (Other)
KW  - real-world practice (Other)
KW  - targeted α-therapy (Other)
KW  - Lutetium (NLM Chemicals)
KW  - Radium (NLM Chemicals)
KW  - Prostate-Specific Antigen (NLM Chemicals)
KW  - Dipeptides (NLM Chemicals)
KW  - Heterocyclic Compounds, 1-Ring (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:36302656
C2  - pmc:PMC10071785
DO  - DOI:10.2967/jnumed.122.264456
UR  - https://inrepo02.dkfz.de/record/275256
ER  -